Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, is a once-weekly prescription combination hormonal contraceptive patch. It delivers a dose of estrogen that is consistent with commonly prescribed combined hormonal contraceptives. Co.'s pipeline consists of two classes of product candidates: Co.'s potential product pipeline consists of two types of product candidates: a progestin-only contraceptive patch and potential Twirla line extensions. These potential product candidates are designed to address market needs and provide additional non-daily contraceptive options. Including AG200-15 Extended Regimen, AG200-SmP, and AG200-15 ER SmP. The AGRX stock yearly return is shown above.
The yearly return on the AGRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AGRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|